<?xml version="1.0" encoding="UTF-8"?>
<p id="Par34">MERS-CoV was first detected in Saudi Arabia in September 2012, which belongs to lineage C of 
 <italic>Betacoronavirus</italic> and binds to the dipeptidyl peptidase 4 (DPP4) receptor [
 <xref ref-type="bibr" rid="CR36">36</xref>]. Based on existing evidence, patients with MERS-CoV infection present with fever; respiratory symptoms, including cough, sputum, and dyspnea; and gastrointestinal symptoms, such as anorexia, nausea, vomiting, abdominal pain, and diarrhea, and general shock or kidney damage may also appear during the illness [
 <xref ref-type="bibr" rid="CR36">36</xref>]. In a retrospective investigation of 12 patients with severe SARS, 11 patients had shock symptoms, and 7 had acute kidney injury [
 <xref ref-type="bibr" rid="CR36">36</xref>]. Another study reported the symptoms of 47 patients with MERS: 12 (26%) had diarrhea, 10 (21%) had vomiting, and 8 (17%) had abdominal pain [
 <xref ref-type="bibr" rid="CR37">37</xref>]. Approximately 25% of patients with MERS have developed diarrhea or abdominal pain at the time of consultation. Some patients initially present with fever and gastrointestinal symptoms, followed by more severe respiratory symptoms [
 <xref ref-type="bibr" rid="CR37">37</xref>]. Based on RNA tests, approximately 14.6% of stool samples from patients with MERS showed positive results [
 <xref ref-type="bibr" rid="CR38">38</xref>].
</p>
